Form 4: Mersana Therapeutics Director Anna Protopapas Executes Stock Transactions Following RSU Vesting

Anna Protopapas, a director at Mersana Therapeutics, executed stock transactions including the acquisition of shares through RSU vesting and a subsequent sale to cover tax obligations.

Summary

• Anna Protopapas, a director at Mersana Therapeutics, acquired 31,250 shares of common stock on January 13, 2025, through the vesting of restricted stock units (RSUs).
• Following the vesting, 11,534 shares were sold on January 14, 2025, at a price of $0.66 per share to cover tax obligations.
• The sale was executed automatically through a 'sell to cover' transaction under a pre-arranged Rule 10b5-1 trading plan.
• After these transactions, Protopapas directly owns 144,869 shares of common stock.
• Additionally, she has indirect ownership of 240,244 shares through the Anna Protopapas Irrevocable Trust and 72,263 shares through the Kinney/Protopapas Family Irrevocable Trust.

Sentiment

Score: 7

Explanation: The document reflects routine transactions related to executive compensation and does not indicate any significant positive or negative sentiment. The use of a 10b5-1 plan is a standard practice.

Industry Context

This is a standard transaction for company directors who receive equity compensation. The use of a 10b5-1 plan is common to avoid insider trading accusations.

Comparison to Industry Standards

• The use of Rule 10b5-1 trading plans is a common practice among corporate executives to manage stock transactions and avoid insider trading concerns, similar to practices at companies like Amgen and Regeneron.
• The vesting of RSUs and subsequent sale to cover taxes is a typical compensation structure seen across the biotechnology industry, comparable to equity grants at companies like Gilead Sciences and Biogen.
• The level of ownership by a director is not unusual for a company of this size and stage, and is similar to ownership levels at comparable companies such as Arcus Biosciences and Iovance Biotherapeutics.

Stakeholder Impact

• The transactions have a minor impact on shareholders as they are part of a pre-arranged plan and do not indicate any change in the company's fundamentals.
• The sale of shares to cover tax obligations is a standard practice and does not negatively impact the company's financial position.

Key Dates

Keywords

Mersana Therapeutics, Anna Protopapas, RSU, Stock Transaction, Rule 10b5-1, Director, Beneficial Ownership, Tax Withholding